Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins 11

• Material Type: 博士論文
• ISSN: 2072-6651
• Title: Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins
• Volume: 13 11
• Author/Editor: Takeuchi, Toshiaki; Okuno, Tsuyoshi; Miyashiro, Ai; Kohda, Tomoko; Miyamoto, Ryosuke; Izumi, Yuishin; Kozaki, Shunji; Kaji, Ryuji
• Author Heading: Takeuchi, Toshiaki; Okuno, Tsuyoshi; Miyashiro, Ai; Kohda, Tomoko; Miyamoto, Ryosuke; Izumi, Yuishin; Kozaki, Shunji; Kaji, Ryuji
• Publication, Distribution, etc.: MDPI
• Publication Date: 2021-11-22
• Publication Date (W3CDTF): 2021-11-22
• Alternative Title: A1型毒素との比較でボツリヌス神経毒素A2型、新規低分子量神経毒素A2NTXの臨床安全性と忍容性
• Periodical title: Toxins
• Degree grantor/type: 徳島大学
• Date Granted: 2022-04-28
• Date Granted (W3CDTF): 2022-04-28
• Dissertation Number: 甲第3638号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第3638号
• Text Language Code: eng
• Subject Heading: botulinum toxin; subtype A2; clinical tolerability; safety; patients
• Target Audience: 一般
• Note (General): All the botulinum type A neurotoxins available for clinical use are of the A1 subtype. We developed a subtype A2 low-molecular-weight (150 kD (kilo Dalton)) neurotoxin (A2NTX) with less spread and faster entry into the motor nerve terminal than A1 in vitro and in vivo. Preliminary clinical studies showed that its efficacy is superior to A1 toxins. We conducted an open study exploring its safety and tolerability profile in comparison with A1LL (LL type A1 toxin, or onabotulinumtoxinA) and a low-molecular-weight (150 kD) A1 neurotoxin (A1NTX). Those who had been using A1LL (n = 90; 50–360 mouse LD50 units) or A1NTX (n = 30; 50–580 units) were switched to A2NTX (n = 120; 25–600 units) from 2010 to 2018 (number of sessions ~27, cumulative doses ~11,640 units per patient). The adverse events for A2NTX included weakness (n = 1, ascribed to alcoholic polyneuropathy), dysphagia (1), local weakness (4), and spread to other muscles (1), whereas those for A1LL or A1NTX comprised weakness (n = 2, A1NTX), dysphagia (8), ptosis (6), local weakness (7), and spread to other muscles (15). After injections, 89 out of 120 patients preferred A2NTX to A1 for the successive sessions. The present study demonstrated that A2NTX had clinical safety up to the dose of 500 units and was well tolerated compared to A1 toxins
• DOI: info:doi/10.3390/toxins13110824; https://doi.org/info:doi/10.3390/toxins13110824
• Persistent ID (NDL): info:ndljp/pid/12304024; https://dl.ndl.go.jp/pid/12304024
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2022-07-05T02:30:21+09:00
• Format (IMT): PDF
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://repo.lib.tokushima-u.ac.jp/117149
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp